ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1815

Leveraging Novel Systemic Sclerosis Disease Signatures to Build a Humanized Drug Discovery Funnel

Lauren Reinke-Breen1, Laura Leys1, Sunhwa Kim2, Lauren Olson1, Anastasia Marinopoulos1, Chris Butler1, Jennifer Van Camp1 and Lisa Hazelwood1, 1AbbVie, North Chicago, IL, 2AbbVie, South San Francisco, CA

Meeting: ACR Convergence 2024

Keywords: Biomarkers, Fibroblasts, Dermal, Gene Expression, Mouse Models, Other, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic sclerosis (SSc) is a chronic, progressive autoimmune disorder with significant morbidity and mortality. The lack of effective therapies for SSc is, in part, due to the poor understanding of the molecular and cellular mechanisms underlying fibrosis pathogenesis. To deepen our understanding of disease progression, we interrogated published transcriptomics datasets to deconvolute molecular signatures of SSc over time. The integrated gene signatures were applied to preclinical models of SSc, enabling optimization of models based upon human disease-relevant endpoints. Antifibrotic agents, including a tool LPAR1 inhibitor, were used for model validation.

Methods: Transcriptomics profiling and enrichment analyses were used to integrate three published datasets (GSE130955, GSE58095, and GSE181549). We constructed novel biomarker maps that model the dysregulation seen in early SSc (mean duration 1.3yr), late SSc (mean duration 7.7yr), and common to both early and late disease. Select biomarkers from these maps were measured in preclinical models. NHDFs (normal human dermal fibroblasts) and full-thickness human skin explants were injured with complex inflammatory-fibrotic cocktails, in the presence or absence of antifibrotic agents. A 28-day bleomycin-induced mouse model of SSc was evaluated, with and without antifibrotic treatment. Across models, gene expression and secreted proteins were measured.

Results: Using published skin transcriptomics datasets, we constructed novel signatures that capture aspects of the pathobiology observed in early and late SSc. We demonstrated that treatment of NHDFs and human skin explants with complex inflammatory-fibrotic cocktails causes an upregulation of multiple genes and proteins identified from these novel SSc signatures, including COL8A1, CTHRC1, MMP-1, and MMP-3. Treatment with a tool LPAR1 inhibitor significantly decreased these endpoints in NHDFs. (Figure 1)

We also assessed the expression of numerous genes in our novel SSc signatures across four time points in a mouse model of bleomycin-induced skin fibrosis to determine whether these changes are recapitulated in this model. Figure 2 highlights genes that were upregulated in both human SSc and the mouse bleo model. Furthermore, we demonstrated that many of the genes that are significantly increased in the skin of bleomycin-treated mice can be significantly decreased by treatment with an LPAR1 inhibitor. (Figure 3) Continuing to identify pathways in the mouse bleomycin model that best reflect changes seen in SSc skin will help improve the translatability of this model.

Conclusion: By profiling three highly-quality SSc skin transcriptomics datasets, we identified key affected pathways and processes throughout SSc pathogenesis. We used these signatures to identify disease-relevant endpoints and guide the optimization of preclinical models to recapitulate key aspects of SSc pathobiology. We also demonstrated that treatment with a tool LPAR1 inhibitor modulates these signatures. These human-centric models will allow us to improve characterization of fibrosis mechanisms and assessment of compound efficacy against key disease processes.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: L. Reinke-Breen: AbbVie/Abbott, 3, 11; L. Leys: AbbVie/Abbott, 3, 11; S. Kim: AbbVie/Abbott, 3; L. Olson: AbbVie/Abbott, 3, 11; A. Marinopoulos: AbbVie/Abbott, 3, 11; C. Butler: None; J. Van Camp: AbbVie/Abbott, 3, 11; L. Hazelwood: AbbVie/Abbott, 3.

To cite this abstract in AMA style:

Reinke-Breen L, Leys L, Kim S, Olson L, Marinopoulos A, Butler C, Van Camp J, Hazelwood L. Leveraging Novel Systemic Sclerosis Disease Signatures to Build a Humanized Drug Discovery Funnel [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/leveraging-novel-systemic-sclerosis-disease-signatures-to-build-a-humanized-drug-discovery-funnel/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/leveraging-novel-systemic-sclerosis-disease-signatures-to-build-a-humanized-drug-discovery-funnel/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology